COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
COMPASS Pathways plc (Nasdaq: CMPS) announced it will release its financial results for Q1 2022 and provide a business update on May 10, 2022. The management will host a conference call at 8:00 AM ET. The call will also be accessible via webcast and archived for 30 days. COMPASS is focused on mental health innovations using its synthetic psilocybin formulation, COMP360, which has received FDA Breakthrough Therapy designation for treatment-resistant depression. The company recently completed a Phase IIb clinical trial, showing statistically significant improvements in depressive symptoms.
- COMP360 received FDA Breakthrough Therapy designation for treatment-resistant depression.
- Successful completion of Phase IIb clinical trial for COMP360, demonstrating significant improvements in depressive symptoms.
- None.
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May 2022.
The management team will host a conference call at 8:00am ET (1:00pm UK) on 10 May. The call can be accessed by dialing (800) 926-7358 from the United States, +1 (212) 231-2914 internationally, and 0800 496 0823 from the UK, followed by the conference ID: 22018578.
The call will also be webcast on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com
Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Enquiries
Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
FAQ
When will COMPASS Pathways release its Q1 2022 financial results?
What is the significance of COMP360 in COMPASS Pathways' pipeline?
What were the results of the Phase IIb clinical trial for COMP360?
How can I access the COMPASS Pathways conference call?
